2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
163
Breast Neoplasms
123
Lung Neoplasms
101
Carcinoma, Non-Small-Cell Lung
83
Glioblastoma
77
Brain Neoplasms
74
Neoplasm Metastasis
68
Glioma
68
Pancreatic Neoplasms
50
Neoplasms
45
Carcinoma, Renal Cell
45
Multiple Myeloma
44
Colorectal Neoplasms
43
Squamous Cell Carcinoma of Head and Neck
39
Lymphoma, Large B-Cell, Diffuse
39
Carcinoma, Hepatocellular
36
Ovarian Neoplasms
34
Melanoma
34
Lymphoma
34
Urinary Bladder Neoplasms
33
Astrocytoma
30
Sarcoma
26
Rectal Neoplasms
26
Uterine Cervical Neoplasms
24
Oropharyngeal Neoplasms
24
Lymphoma, Follicular
24
Central Nervous System Neoplasms
24
Lymphoma, Non-Hodgkin
23
Triple Negative Breast Neoplasms
22
Gliosarcoma
22
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Observation
3
Neoadjuvant Therapy
3
Epirubicin
3
Endoscopy
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Monatide (IMS 3015)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Magnetic Resonance Spectroscopy
×
Clear all
NCT01956513
2013-10-08
ADC
Centre Jean Perrin
Phase NA
Withdrawn